Mr. Matthew W. Foehr is President, Chief Operating Officer of the Company. He served as our Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior ...
Reuters · 1y
Investors who purchased shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) have certain options and for certain ... and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information …
Ligand Pharmaceuticals Inc (LGND): LGND stock is up 4.4% today and up 22.6% in the ... Article printed from InvestorPlace Media, http://investorplace.com/2014/10/hottest-healthcare-stocks-now-sgen-nbix-lgnd-achc-sgen-nbix-lgnd/.
That creates more demand for the stock, which pushes it higher, which forces more shorts to buy the shares and so on and so on. Look at Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The stock has had a big run this year, especially since June. As of June 14 ...
There have been repeated insider purchases in CLUB since November. The stock appreciates as consumer sentiment and spending improves. 3. Ligand Pharma (LGND): Imitating the substantial insider purchases we reported paid off. The stock rose 11% in the week ...
The MLA Amendment also amended the upfront payments to the Company of Viking capital stock. If Viking completes an initial public offering (an “IPO”), Viking will issue to the Company a number of shares of Viking common stock based on …
Cloud Computing Magazine Click here to read latest issue Subscribe for FREE - Click Here IoT EVOLUTION MAGAZINE Click here to read latest issue Subscribe for FREE - Click Here
TMCnet · 7y
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has entered into a definitive merger agreement to acquire Pharmacopeia (NASDAQ: PCOP) in a deal valued up to $70 million. The transaction is structured as a stock-for-stock exchange for thefirst part of ...
Lemelson Capital chief investment officer Emmanuel Lemelson recently increased his short position in Ligand Pharmaceuticals (NYSE: LGND) after its second quarter earnings report. “Any company whose EPS is down 76 percent year over year while its stock ...
Loeb held 7.725 million shares in LGND for the quarter ended December 31, 2006. The firm disclosed that on March 26, 2007, certain of the Funds sold 5,720,000 shares, representing 5.66% of the Common Stock outstanding, and the Management Company on behalf ...